WO2004104595A3 - Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd) - Google Patents

Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd) Download PDF

Info

Publication number
WO2004104595A3
WO2004104595A3 PCT/EP2004/004964 EP2004004964W WO2004104595A3 WO 2004104595 A3 WO2004104595 A3 WO 2004104595A3 EP 2004004964 W EP2004004964 W EP 2004004964W WO 2004104595 A3 WO2004104595 A3 WO 2004104595A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
pepd
therapeutics
diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/004964
Other languages
French (fr)
Other versions
WO2004104595A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to EP04731927A priority Critical patent/EP1629282A2/en
Publication of WO2004104595A2 publication Critical patent/WO2004104595A2/en
Publication of WO2004104595A3 publication Critical patent/WO2004104595A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human PEPD which is associated with the cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, metabolic diseases, inflammatory diseases, cancer disorders, neurological disorders, respiratory diseases, hematological disorders, urological disorders and endocrinological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, metabolic diseases, inflammatory diseases, cancer disorders, neurological disorders, respiratory diseases, hematological disorders, urological disorders and endocrinological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PEPD as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/004964 2003-05-22 2004-05-10 Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd) Ceased WO2004104595A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04731927A EP1629282A2 (en) 2003-05-22 2004-05-10 Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011593 2003-05-22
EP03011593.5 2003-05-22

Publications (2)

Publication Number Publication Date
WO2004104595A2 WO2004104595A2 (en) 2004-12-02
WO2004104595A3 true WO2004104595A3 (en) 2005-04-28

Family

ID=33462086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/004964 Ceased WO2004104595A2 (en) 2003-05-22 2004-05-10 Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd)

Country Status (2)

Country Link
EP (1) EP1629282A2 (en)
WO (1) WO2004104595A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3001805B1 (en) * 2013-02-01 2015-02-20 Biomerieux Sa METHOD FOR DETECTING COLORECTAL CANCER
WO2015031119A1 (en) * 2013-08-26 2015-03-05 Health Research, Inc. Method for prophylaxis and/or treatment of erbb2 positive cancers
CN107075490A (en) * 2014-08-20 2017-08-18 健康研究公司 Methods for preventing and/or treating ERBB1-positive cancers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011799A2 (en) * 1997-09-02 1999-03-11 Medical College Of Georgia Research Institute, Inc. Human aminopeptidase p gene
WO2002061131A2 (en) * 2000-12-04 2002-08-08 Bristol-Myers Squibb Company Human single nucleotide polymorphisms
US20020137120A1 (en) * 2000-10-31 2002-09-26 Brown Nancy J. Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor-and vasopeptidase inhibitor-associated angioedema

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011799A2 (en) * 1997-09-02 1999-03-11 Medical College Of Georgia Research Institute, Inc. Human aminopeptidase p gene
US20020137120A1 (en) * 2000-10-31 2002-09-26 Brown Nancy J. Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor-and vasopeptidase inhibitor-associated angioedema
WO2002061131A2 (en) * 2000-12-04 2002-08-08 Bristol-Myers Squibb Company Human single nucleotide polymorphisms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VENEMA ET AL: "Cloning and tissue distribution of human membrane-bound aminopeptidase P", BIOCHIMICA ET BIOPHYSICA ACTA . GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol. 1354, no. 1, 1997, pages 45 - 48, XP002095023, ISSN: 0167-4781 *

Also Published As

Publication number Publication date
EP1629282A2 (en) 2006-03-01
WO2004104595A2 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2004104216A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2005022146A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 13 (klk13)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005114207A3 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase n (anpep)
WO2004097358A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005078117A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6)
WO2005085466A3 (en) Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005075662A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
WO2004097034A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 4 (tmprss4)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
WO2005040401A3 (en) Diagnostics and therapeutics for diseases associated with mosaic serine protease (msp)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2006013016A3 (en) Diagnostics and therapeutics for diseases associated with eosinophil serine protease 1 (prss21)
WO2005095631A3 (en) Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2006013014A3 (en) Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)
WO2005052586A3 (en) Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 3 (kcnk3)
WO2005076003A3 (en) Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004731927

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004731927

Country of ref document: EP